Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
by
Urmeel H. Patel
,
Muhammad A. Mir
,
Jeffrey K. Sivik
,
Divisha Raheja
,
Manoj K. Pandey
and
Giampaolo Talamo
* 
Penn State Hershey Cancer Institute, 500 University Drive, Hershey, PA 17033, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(1), 5704; https://doi.org/10.4081/hr.2015.5704
Submission received: 7 November 2014
/
Revised: 9 February 2015
/
Accepted: 17 February 2015
/
Published: 3 March 2015
Abstract
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
Share and Cite
MDPI and ACS Style
Patel, U.H.; Mir, M.A.; Sivik, J.K.; Raheja, D.; Pandey, M.K.; Talamo, G. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematol. Rep. 2015, 7, 5704. https://doi.org/10.4081/hr.2015.5704
AMA Style
Patel UH, Mir MA, Sivik JK, Raheja D, Pandey MK, Talamo G. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematology Reports. 2015; 7(1):5704. https://doi.org/10.4081/hr.2015.5704
Chicago/Turabian StylePatel, Urmeel H., Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey, and Giampaolo Talamo. 2015. "Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma" Hematology Reports 7, no. 1: 5704. https://doi.org/10.4081/hr.2015.5704
